Technology
Health
Pharmaceutical

Galmed Pharmaceuticals

$8.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.16 (-1.80%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell GLMD and other stocks, options, ETFs, and crypto commission-free!

About

Galmed Pharmaceuticals Ltd. Ordinary Shares, also called Galmed Pharmaceuticals, is a clinical-stage biopharmaceutical company. Read More It focuses on the development of the liver targeted stearoyl-coenzyme A desaturase-1 modulator Aramchol, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. The Aramchol is a synthetic conjugate of cholic acid, or a type of bile acid, and arachidic acid, or a type of saturated fatty acid, both of which, in their non-synthetic forms, are naturally occurring. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Employees
21
Headquarters
Tel Aviv, Tel Aviv
Founded
2000
Market Cap
186.65M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
295.55K
High Today
$8.99
Low Today
$8.35
Open Price
$8.81
Volume
105.27K
52 Week High
$27.06
52 Week Low
$4.84

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
Therapy
2014 IPO
Asia (Non-China)

News

Seeking AlphaMar 14

Galmed Pharmaceuticals Ltd.'s (GLMD) CEO Allen Baharaff on Q4 2018 Results - Earnings Call Transcript

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Q4 2018 Results Earnings Conference Call March 13, 2019 8:30 AM ET Company Participants Paul Arndt - Managing Director, LifeSci Advisors Allen Baharaff - Co-Founder, President, Chief Executive Officer Liat Hayardeny - Chief Scientific Officer Tali Gorfine - Chief Medical Officer Yohai Stenzler - Chief Financial Officer Conference Call Participants Steven Seedhouse - Raymond James Adam Walsh - Stifel Ed Arce - H.C. Wainwright Mayank Mamtani - B. Riley Car...

57
Yahoo FinanceMar 13

Galmed Pharmaceuticals (GLMD) Reports Q4 Loss, Misses Revenue Estimates

Galmed Pharmaceuticals (GLMD) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.27 per share a year ago.

9
PR NewswireMar 13

Galmed Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

TEL AVIV, Israel, March 13, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, today reported financial results for the three and twelve months ended December 31, 2018. The Company will host a conference call and webcast at 08:30 ET today. Business Update Updates on progress...

69

Earnings

-$0.27
-$0.20
-$0.12
-$0.05
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.13 per share
Actual
-$0.18 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.